Optimism that Greece and its creditors were close to finalizing a deal sent the markets soaring during the midday with the Dow climbing 105 points to 18,121. Nasdaq gained 32 points to 5,149.
On the upside
Epizyme (Nasdaq: EPZM) reported positive results from an ongoing Phase 1 study of tazemetostat to treat patients with advanced B-cell non-Hodgkin lymphomas and solid tumors.
JMP Securities initiated coverage of Akebia Therapeutics (Nasdaq: AKBA) with a Market Outperform rating.
Transgenomic (Nasdaq: TBIO) will launch up to six new genetic cancer tests this year.
On the downside
William Blair downgraded Polycom (Nasdaq: PLCM) from a Market Perform rating to an Underperform rating.
Profit taking continued to weigh down shares of Synergy Pharmaceuticals (Nasdaq: SGYP).
Shares of FuelCell Energy (Nasdaq: FCEL) extended its losses.
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 3 on the NYSE and by more than 5 to 3 on Nasdaq. The broader S&P 500 gained 12 points to 2122. Bitcoin rose $3 to $246.
Greece near deal, markets soar
June 22, 2015 at 14:20 PM EDT